NCT00141180已完成1 期
Placebo-Controlled, Randomized, Parallel Group, Multiple-Dose Study to Evaluate the Effects of CP-481,715 on Clinical Response and Cellular Infiltration Following Contact Allergen Challenge to the Skin of Nickel Allergic Subjects.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 48
- 试验地点
- 6
- 主要终点
- Effect of CP-481,715 on clinical response and cell infiltration after nickel challenge
研究概览
简要总结
To evaluate the suitability of contact allergy as a method for the evaluation of c-chemokine receptor-1 antagonist.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •A history of nickel allergy confirmed by a visual positive reaction (graded at least ++) to T.R.U.E. TEST.
排除标准
- •Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding contact allergic dermatitis or untreated, asymptomatic, seasonal allergies at time of dosing).
结局指标
主要结局
Effect of CP-481,715 on clinical response and cell infiltration after nickel challenge
次要结局
未报告次要终点
研究者
研究点 (6)
Loading locations...
相似试验
已完成
2 期
Safety and Efficacy Study of Eculizumab in Patients With Mild Allergic AsthmaAllergic AsthmaNCT00485576Alexion Pharmaceuticals, Inc.21
已完成
4 期
Evaluation of Prednisolone in a Modified Conjunctival Allergen Challenge ModelChronic Allergic ConjunctivitisNCT01730872ORA, Inc.16
已完成
不适用
Explorative study: the relevance of contact allergy to isobornyl acrylate in people with an other acrylate allergyallergic contact dermatitiscontact eczema10014982NL-OMON35745niversitair Medisch Centrum Groningen20
招募中
不适用
Clinical evaluation of allergen component specific IgE test for nuts and fruits allergy patientsFood allergyJPRN-UMIN000016457Department of Dermatology, Yokohama City University hospital54
已完成
4 期
Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) ModelAllergic ConjunctivitisNCT01534195ORA, Inc.11